In last trading session, Y-Mabs Therapeutics Inc (NASDAQ:YMAB) saw 0.33 million shares changing hands with its beta currently measuring 0.64. Company’s recent per share price level of $5.72 trading at -$0.32 or -5.30% at ring of the bell on the day assigns it a market valuation of $256.20M. That closing price of YMAB’s stock is at a discount of -265.38% from its 52-week high price of $20.90 and is indicating a premium of 2.1% from its 52-week low price of $5.60.

For Y-Mabs Therapeutics Inc (YMAB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.18. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.13 in the current quarter.

Y-Mabs Therapeutics Inc (NASDAQ:YMAB) trade information

Upright in the red during last session for losing -5.30%, in the last five days YMAB remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $5.72 price level, adding 13.98% to its value on the day. Y-Mabs Therapeutics Inc’s shares saw a change of -26.95% in year-to-date performance and have moved -7.29% in past 5-day. Y-Mabs Therapeutics Inc (NASDAQ:YMAB) showed a performance of -7.59% in past 30-days.

Wall Street analysts have assigned a consensus price target of 24 to the stock, which implies a rise of 76.17% to its current value. Analysts have been projecting 24 as a low price target for the stock while placing it at a high target of 24. It follows that stock’s current price would drop -319.58% in reaching the projected high whereas dropping to the targeted low would mean a loss of -319.58% for stock’s current value.

Y-Mabs Therapeutics Inc (YMAB) estimates and forecasts

This year revenue growth is estimated to rise 4.22% from the last financial year’s standing.

8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 26.7M for the same. And 7 analysts are in estimates of company making revenue of 24.37M in the next quarter. Company posted 23.36M and 19.93M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 20.06% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -23.22% while estimates for its earnings growth in next 5 years are of -19.55%.

Y-Mabs Therapeutics Inc (NASDAQ:YMAB)’s Major holders

PARADIGM BIOCAPITAL ADVISORS LP is the top institutional holder at YMAB for having 3.87 million shares of worth $46.76 million. And as of 2024-06-30, it was holding 8.7923 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 2.94 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.7126 of outstanding shares, having a total worth of $35.5 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.04 shares of worth $5.95 million or 2.32% of the total outstanding shares. The later fund manager was in possession of 1.03 shares on Nov 30, 2024 , making its stake of worth around $5.91 million in the company or a holder of 2.31% of company’s stock.